IPRD funded research by Jerome Irianto
Pediatric glioblastoma: Brain tumors are the second most common form of cancer in children, and glioblastoma multiforme (GBM) is one of the most aggressive types of brain tumors. GBM occurs in 3-15% of pediatric patients and the 5-year survival rate is less than 20%. GBM cells are highly invasive and can escape surgical resection, which leads to relapse. The crucial role of tumor cell-synthesized type I collagen in GBM growth and invasion has been recently elucidated, suggesting it as a novel therapeutic target to treat GBM. This research project examines the potential for developing a novel inhibitor of type 1 collagen synthesis as an antitumor drug for the treatment of pediatric GBM.
Resources